Download
fncel-15-705618.pdf 673,72KB
WeightNameValue
1000 Titel
  • Decreased Neurofilament L Chain Levels in Cerebrospinal Fluid and Tolerogenic Plasmacytoid Dendritic Cells in Natalizumab-Treated Multiple Sclerosis Patients – Brief Research Report
1000 Autor/in
  1. Moraes, Adriel S. |
  2. Boldrini, Vinicius O. |
  3. Dionete, Alliny C. |
  4. Andrade, Marilia D. |
  5. Longhini, Ana Leda F. |
  6. Santos, Irene |
  7. Lima, Amanda D. R. |
  8. Silva, Veronica A. P. G. |
  9. Dias Carneiro, Rafael P. C. |
  10. Quintiliano, Raphael P. S. |
  11. Ferrari, Breno B. |
  12. Damasceno, Alfredo |
  13. Pradella, Fernando |
  14. Farias, Alessandro S. |
  15. Tilbery, Charles P. |
  16. Domingues, Renan B. |
  17. Senne, Carlos |
  18. Fernandes, Gustavo B. P. |
  19. von Glehn, Felipe |
  20. Brandão, Carlos Otavio |
  21. Stella, Carla R. A. V. |
  22. Santos, Leonilda M. B. |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-07-26
1000 Erschienen in
1000 Quellenangabe
  • 15:705618
1000 Copyrightjahr
  • 2021
1000 Embargo
  • 2022-01-28
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.3389/fncel.2021.705618 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350727/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Abstract/Summary
  • <jats:sec><jats:title>Background</jats:title><jats:p>Neurofilament Light (NfL) chain levels in both cerebrospinal fluid (CSF) and serum have been correlated with the reduction of axonal damage in multiple sclerosis (MS) patients treated with Natalizumab (NTZ). However, little is known about the function of plasmacytoid cells in NTZ-treated MS patients.</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>To evaluate CSF NfL, serum levels of soluble-HLA-G (sHLA-G), and eventual tolerogenic behavior of plasmacytoid dendritic cells (pDCs) in MS patients during NTZ treatment.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>CSF NfL and serum sHLA-G levels were measured using an ELISA assay, while pDCs (BDCA-2<jats:sup>+</jats:sup>) were accessed through flow cytometry analyses.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>CSF levels of NfL were significantly reduced during NTZ treatment, while the serum levels of sHLA-G were increased. Moreover, NTZ treatment enhanced tolerogenic (HLA-G<jats:sup>+</jats:sup>, CD274<jats:sup>+</jats:sup>, and HLA-DR<jats:sup>+</jats:sup>) molecules and migratory (CCR7<jats:sup>+</jats:sup>) functions of pDCs in the peripheral blood.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>These findings suggest that NTZ stimulates the production of molecules with immunoregulatory function such as HLA-G and CD274 programmed death-ligand 1 (PD-L1) which may contribute to the reduction of axonal damage represented by the decrease of NfL levels in patients with MS.</jats:p></jats:sec>
1000 Sacherschließung
lokal neurofilament light chain
lokal PD-L1
lokal HLA-G
lokal Neuroscience
lokal neuroinflammation
lokal HLA-DR
lokal cerebrospinal fluid
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/TW9yYWVzLCBBZHJpZWwgUy4=|https://frl.publisso.de/adhoc/uri/Qm9sZHJpbmksIFZpbmljaXVzIE8u|https://frl.publisso.de/adhoc/uri/RGlvbmV0ZSwgQWxsaW55IEMu|https://frl.publisso.de/adhoc/uri/QW5kcmFkZSwgTWFyaWxpYSBELg==|https://frl.publisso.de/adhoc/uri/TG9uZ2hpbmksIEFuYSBMZWRhIEYu|https://frl.publisso.de/adhoc/uri/U2FudG9zLCBJcmVuZQ==|https://frl.publisso.de/adhoc/uri/TGltYSwgQW1hbmRhIEQuIFIu|https://frl.publisso.de/adhoc/uri/U2lsdmEsIFZlcm9uaWNhIEEuIFAuIEcu|https://frl.publisso.de/adhoc/uri/RGlhcyBDYXJuZWlybywgUmFmYWVsIFAuIEMu|https://frl.publisso.de/adhoc/uri/UXVpbnRpbGlhbm8sIFJhcGhhZWwgUC4gUy4=|https://frl.publisso.de/adhoc/uri/RmVycmFyaSwgQnJlbm8gQi4=|https://frl.publisso.de/adhoc/uri/RGFtYXNjZW5vLCBBbGZyZWRv|https://frl.publisso.de/adhoc/uri/UHJhZGVsbGEsIEZlcm5hbmRv|https://frl.publisso.de/adhoc/uri/RmFyaWFzLCBBbGVzc2FuZHJvIFMu|https://frl.publisso.de/adhoc/uri/VGlsYmVyeSwgQ2hhcmxlcyBQLg==|https://frl.publisso.de/adhoc/uri/RG9taW5ndWVzLCBSZW5hbiBCLg==|https://frl.publisso.de/adhoc/uri/U2VubmUsIENhcmxvcw==|https://frl.publisso.de/adhoc/uri/RmVybmFuZGVzLCBHdXN0YXZvIEIuIFAu|https://frl.publisso.de/adhoc/uri/dm9uIEdsZWhuLCBGZWxpcGU=|https://frl.publisso.de/adhoc/uri/QnJhbmTDo28sIENhcmxvcyBPdGF2aW8=|https://frl.publisso.de/adhoc/uri/U3RlbGxhLCBDYXJsYSBSLiBBLiBWLg==|https://frl.publisso.de/adhoc/uri/U2FudG9zLCBMZW9uaWxkYSBNLiBCLg==
1000 Hinweis
  • DeepGreen-ID: d85fa8fb9a6243c2be074e2d1102c8e0 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Fundação de Amparo à Pesquisa do Estado de São Paulo |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Fundação de Amparo à Pesquisa do Estado de São Paulo |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6476806.rdf
1000 Erstellt am 2024-05-14T14:44:49.573+0200
1000 Erstellt von 322
1000 beschreibt frl:6476806
1000 Zuletzt bearbeitet Wed May 15 08:41:19 CEST 2024
1000 Objekt bearb. Wed May 15 08:41:19 CEST 2024
1000 Vgl. frl:6476806
1000 Oai Id
  1. oai:frl.publisso.de:frl:6476806 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source